|
Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial. |
|
|
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical |
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Pfizer; Roche/Genentech |
Speakers' Bureau - Novartis; Pfizer; Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Dompè; Ignyta; Novartis; Pfizer; SERVIER; Tiziana Life Sciences |
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; SERVIER |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar; Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Merck; Merck Sharp & Dohme; Novartis; Roche; Sandoz; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Roche; Takeda |
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Merck; Merck Sharp & Dohme; Novartis; Roche; Sandoz; Takeda |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck KGaA; MSD; Roche |
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Roche; Sanofi; Servier |
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Roche (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Modra Pharmaceuticals |
Stock and Other Ownership Interests - Modra Pharmaceuticals |
Research Funding - Dutch Cancer Society (Inst) |
|
|
Honoraria - Abbvie; AstraZeneca; Genentech/Roche; Immunomic Therapeutics; Kazia Therapeutics; Lilly; Puma Biotechnology; Vascular Biogenics; VBI Vaccines; ZIOPHARM Oncology |
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech/Roche; Immunomic Therapeutics; Kazia Therapeutics; Lilly; Puma Biotechnology; Vascular Biogenics; VBI Vaccines; ZIOPHARM Oncology |
|
Research Funding - Abbvie; Agios; AstraZeneca; BeiGene; Genentech/Roche; Kazia Therapeutics; Merck; Novartis; Oncoceutics; VBI Vaccines |
|
|
|
|
|
|
|
|
Consulting or Advisory Role - MedImmune |
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Vegenics (Inst) |
Travel, Accommodations, Expenses - Bayer; PharmaMar |